Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alector, Inc. - Common Stock (NQ:ALEC)

2.715 +0.125 (+4.83%)
Streaming Delayed Price Updated: 1:10 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alector, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
US Stocks Mixed; Best Buy Posts Downbeat Earnings
 
Via Benzinga
Leslie's Posts Weak Results, Joins Zoom Video And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Recap: Alector Q4 Earnings
 
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
From Alector, Inc.
Via GlobeNewswire
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Earnings Outlook For Alector
 
Via Benzinga
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Alector, Inc.
Via GlobeNewswire
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation 
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024
ALEC stock results show that Alector beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally 
From Alector, Inc.
Via GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.